Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering novel T-cell therapies for cancer. They utilize a proprietary T-cell receptor (TCR) platform to engineer T-cells that can identify and target cancer cells, aiming to significantly impact cancer treatment outcomes. Their pipeline includes therapies for various solid tumor types.